The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
Open accessAbstract
Purpose: Vascular endothelial growth factor (VEGF) seems to be a promoter of tumor progression for epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). We conducted a phase II trial to assess the efficacy and tolerability of single-agent bevacizumab, an anti-VEGF monoclonal antibody. Patients and Methods: Eligible patients had persistent or recurrent EOC/PPC after one to two prior cytotoxic regimens, measurable disease, and Gynecologic Oncology Group performance status of at least 2. Treatment consisted of bevacizumab 15 mg/kg intravenously every 21 days until disease progression or prohibitive toxicity. Primary end points were progression-free survival (PFS) at 6 months and clinical response. Results: The study consisted of 62 eligible and assessable patients, median age 57 years, 41 (66.1%) having received two prior regimens and 36 (58.1%) considered platinum resistant. Grade 3 adverse events at least possibly related to bevacizumab were hematologic (1), GI (3), hypertension (6), thromboembolism (1), allergy (2), hepatic (1), pain (3), coagulation (1), constitutional (1), and dyspnea (1). Grade 4 adverse events included pulmonary embolus (1), vomiting and constipation (1), and proteinuria (1). Thirteen patients (21.0%) experienced clinical responses (two complete, 11 partial; median response duration, 10 months), and 25 (40.3%) survived progression free for at least 6 months. Median PFS and overall survival were 4.7 and 17 months, respectively. There was no significant association of prior platinum sensitivity, age, number of prior chemotherapeutic regimens, or performance status with the hazard of progression or death. Conclusion: Bevacizumab seems to be well tolerated and active in the second- and third-line treatment of patients with EOC/PPC and merits phase III investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,314
Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,573
Molecular and biological properties of vascular endothelial growth factor
Ferrara, N. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900019 · Cited by 1,158
Gorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Mauceri, H. J., Salloum, R. M., Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., et al. (1999) · PubMed · Cited by 947
Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Holmgren, E., Benjamin, R., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
Lee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 677
Tumor angiogenesis in advanced stage ovarian carcinoma.
Hollingsworth, H. C., Kohn, E. C., Steinberg, S. M., Rothenberg, M. L., & Merino, M. J. (1995) · Europe PMC (PubMed Central) · Cited by 386
Expression of Angiogenesis-Related Genes and Progression of Human Ovarian Carcinomas in Nude Mice
Yoneda, J., Kuniyasu, H., Price, J. E., Bucana, C. D., Fidler, I. J., & Crispens, M. A. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.6.447 · Cited by 375
Vascular endothelial growth factor expression in early stage ovarian carcinoma
Paley, P. J., Staskus, K. A., Gebhard, K., Mohanraj, D., Twiggs, L. B., Carson, L. F., & Ramakrishnan, S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970701)80:1<98::aid-cncr13>3.0.co;2-a · Cited by 364
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O’Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2 · Cited by 344
Fan, F., Wey, J. S., McCarty, M. F., Belcheva, A., Liu, W., Bauer, T. W., Somcio, R. J., Wu, Y., Hooper, A., Hicklin, D. J., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208246 · Cited by 342
Byrne, A. T., Ross, L. H., Holash, J., Nakanishi, M., Hu, L., Hofmann, J., Yancopoulos, G. D., & Jaffe, R. B. (2003) · PubMed · Cited by 310
Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question
Whelan, T., & Levine, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.955 · Cited by 304
Pentecost, M. J., Criqui, M. H., Dorros, G., Goldstone, J., Johnston, K. W., Martin, E. C., Ring, E. J., & Spies, J. B. (1994) · Circulation · doi:10.1161/01.cir.89.1.511 · Cited by 303
Price, D. J., Miralem, T., Jiang, S., Steinberg, R., & Avraham, H. K. (2001) · PubMed · Cited by 243
Decaussin, M., Sartelet, H., Robert, C., Moro, D., Claraz, C., Brambilla, C., & Brambilla, E. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199908)188:4<369::aid-path381>3.0.co;2-x · Cited by 212
Expression of vascular endothelial growth factor receptors in human prostate cancer
Ferrer, F. A., Miller, L. J., Lindquist, R., Kowalczyk, P., Laudone, V. P., Albertsen, P. C., & Kreutzer, D. L. (1999) · Urology · doi:10.1016/s0090-4295(99)00156-9 · Cited by 197
Hu, L., Hofmann, J., Zaloudek, C., Ferrara, N., Hamilton, T., & Jaffe, R. B. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64467-7 · Cited by 161
VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma
Chen, H., Ye, D.-F., Xie, X., Chen, B., & Lü, W. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.05.056 · Cited by 146
Monk, B. J., Han, E. S., Josephs-Cowan, C. A., Pugmire, G., & Burger, R. A. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.05.006 · Cited by 140
Self-citationBevacizumab combination therapy in recurrent, platinum‐refractory, epithelial ovarian carcinoma
Wright, J. D., Hagemann, A. R., Rader, J. S., et al. (2006) · Cancer · doi:10.1002/cncr.21969 · Cited by 128
The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma
Numnum, T. M., Rocconi, R. P., Whitworth, J. M., & Barnes, M. N. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.05.018 · Cited by 123
E2100: A Phase III Trial of Paclitaxel Versus Paclitaxel/Bevacizumab for Metastatic Breast Cancer
Miller, K. D. (2003) · Clinical Breast Cancer · doi:10.3816/cbc.2003.n.007 · Cited by 118
Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer
Cohn, D. E., Valmadre, S., Resnick, K. E., Eaton, L. A., Copeland, L. J., & Fowler, J. M. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.01.030 · Cited by 96
Cited by
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Self-citationA Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Curcumin and cancer: An “old-age” disease with an “age-old” solution
Anand, P., Sundaram, C., Jhurani, S., Kunnumakkara, A. B., & Aggarwal, B. B. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.025 · Cited by 1,132
Metadata
- Authors
- Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-11-20
- Volume
- 25
- Issue
- 33
- Pages
- 5165-5171
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2105651363
- Cited by
- 882
- References
- 26
- FWCI
- 87.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.